<del id="tdllb"><th id="tdllb"><ins id="tdllb"></ins></th></del>
<strike id="tdllb"></strike><strike id="tdllb"><dl id="tdllb"></dl></strike>
<span id="tdllb"></span>
<span id="tdllb"><video id="tdllb"><ruby id="tdllb"></ruby></video></span><span id="tdllb"></span>
<strike id="tdllb"><dl id="tdllb"></dl></strike>
<strike id="tdllb"><dl id="tdllb"></dl></strike><span id="tdllb"><dl id="tdllb"></dl></span>
<strike id="tdllb"><dl id="tdllb"><del id="tdllb"></del></dl></strike>
<span id="tdllb"><dl id="tdllb"><ruby id="tdllb"></ruby></dl></span> <span id="tdllb"></span>
<strike id="tdllb"><i id="tdllb"><cite id="tdllb"></cite></i></strike><strike id="tdllb"><dl id="tdllb"></dl></strike><strike id="tdllb"><dl id="tdllb"></dl></strike>

THE MOST FORMIDABLE
HEALTH CHALLENGES DON'T
FALL NEATLY IN ONE BUCKET

We are focused on addressing a broad range of serious medical conditions including ophthalmology, cancer, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases. Our industry-leading research and development engine enables us to develop all potential drug candidates from within our own labs.

  • 20+
    product candidates
    in clinical development
    across multiple therapeutic areas
  • 100%
    of drug candidates
    invented and
    developed in-house
  • CARDIOVASCULAR AND
    METABOLISM

  • INFECTIOUS DISEASES

  • Cardiovascular and metabolic disorders encompass a large number of diseases, including coronary artery disease and diabetes. Our current clinical programs focus on treating cardiovascular disease, the number one cause of morbidity and mortality in the United States and other developed countries, and on muscle-growth disorders.

  • We are advancing new approaches to address serious infections that impact vulnerable populations.

    In an increasingly interconnected world, infectious diseases are able to spread more quickly than in the past, enhancing their threat to global health and elevating the need for new treatments that are safe, effective and easily deployed.

    We?leverage?our proprietary?VelociSuite? ‘rapid response’ technologies to create novel fully human monoclonal antibody?treatments, with the goal of addressing a number of common and newly emerging infectious diseases, such as COVID-19, Ebola and the Middle East respiratory syndrome (MERS) coronavirus.

  • INFLAMMATION AND
    IMMUNOLOGY

  • ONCOLOGY

  • Inflammation is the body's natural protective response against injury and infections, including those caused by bacteria and viruses.

    But inflammation can also occur when the immune system triggers an inappropriate inflammatory response to the body's own cells, or responds excessively to external irritants such as pollen or certain foods. This inflammatory response is usually accompanied by the overproduction of certain proteins called cytokines, including interleukins, and can result in chronic and

    debilitating disease conditions such as rheumatoid arthritis, atopic dermatitis or asthma.

    One therapeutic approach is to block the actions of the cytokines that play a role in the development of these diseases.

  • Despite decades of progress, cancer still remains one of the world's most serious health problems.

    Our approach to cancer is multifaceted:

    • Immuno-Oncology works by unleashing the body's own immune system to eliminate or control cancer. We believe the most successful approaches will combine multiple innovative therapies acting on different pathways and targets, both in the patient's tumor as well as in their immune response, to precisely tailor the best treatments to the individual. We are currently exploring multiple approaches, including checkpoint inhibitors and bispecific antibodies
    • Anti-angiogenesis is the disruption of the blood flow to tumors by inhibiting the formation of new blood vessels. We continue to investigate the potential of novel approaches to inhibit angiogenesis, as well as the possibility of
    • combination approaches that benefit from blocking angiogenesis and altering the tumor microenvironment
    • Antibody drug conjugates (ADCs) are novel combination therapies that enable the selective killing of cancer cells by joining cancer-targeting antibodies with a highly potent chemotherapy, or "warhead." ADCs are designed to take advantage of both the specificity of antibodies and the cancer-killing power of cytotoxic agents
    • Cancer cell dependencies are mutant or aberrant signaling pathways that are required by cancer cells for growth and survival, as a result of their specific oncogenic mutations. We are exploring novel antibody technologies to better target cancer cell dependencies
  • OPHTHALMOLOGY

  • PAIN

  • We have a long-standing commitment to the treatment of serious, vision-threatening diseases.

    Our R&D programs target a number of mechanisms in retinal diseases in unique combinations with anti-Vascular Endothelial Growth Factor (VEGF) therapy, which employs Regeneron's proprietary Trap technology and is currently the standard-of-care for a number of retinal conditions. The VEGF protein is necessary to stimulate the formation of blood vessels that supply

    nutrients to tissues. However, excessive VEGF production can lead to retinal conditions in which blood vessels grow abnormally, become fragile, and vision is threatened due to fluid and blood leaking into surrounding tissue. If untreated, the swelling can damage cells, create blind spots in central vision and lead to permanent vision loss.

  • We are advancing new non-opioid treatment options for patients suffering from a range of chronic pain conditions, including osteoarthritis pain and chronic back pain.

    Many of these patients are currently treated with opioid medicines, which can often come with unwanted side effects and the potential for abuse. We are leading the discovery and characterization of a new class of proteins, called

    neurotrophins, which promote the growth of nerve cells. Members of this family of proteins include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and others.

  • RARE DISEASES

  • At Regeneron, we believe in following sound and innovative science. We pursue foundational scientific research that can impact diseases with both large and small groups of patients. To do this research, we leverage cutting-edge research tools and resources such as the Regeneron Genetics Center to further understand the genetic variations that may protect someone from a disease or make them more susceptible. We then use Regeneron-invented technologies to further understand the root causes of disease and to identify potential new therapies. Through this approach, we have created numerous approved and investigational medicines for patients with rare and ultra-rare conditions.

    Our areas of rare disease research include:

    • Cryopyrin-Associated Periodic Syndromes (CAPS): CAPS is a group of illnesses characterized by lifelong, recurrent symptoms of rash, fever/chills, joint pain, eye redness/pain and fatigue. Our first FDA-approved drug, launched in 2008, treats aspects of this auto-inflammatory syndrome.
    • Fibrodysplasia Ossificans Progressiva (FOP): FOP is a progressive, severely disabling, life-altering disease in which muscles, ligaments, tendons and other connective tissues are transformed into bone. Scientists in our Skeletal Diseases Therapeutic Focus Area have been investigating FOP and related conditions for 20 years. Based on our novel discoveries about the functioning of this ultra-rare disease (with only 800 known patients in the world), we are studying a new, Regeneron-invented investigational treatment for people living with this condition.
    • Homozygous familial hypercholesterolemia (HoFH): People with HoFH have an inherited form of extremely high cholesterol and are unable to process the body's natural supply of cholesterol in the liver. Very high levels of LDL cholesterol can block arteries (atherosclerosis) and lead to a heart attack or stroke at a very young age. We are conducting various studies in HoFH, including an investigational, fully-human monoclonal antibody that specifically binds to and blocks a key protein in regulating LDL cholesterol levels.
    • Paroxysmal nocturnal hemoglobinuria (PNH): PNH is an ultra-rare, chronic, life-threatening disease in which genetic variants lead to increased risk for destruction of red blood cells, resulting in a range of symptoms including fatigue, shortness of breath and blood clots. We are exploring an investigational, fully-human monoclonal antibody designed to block and prevent the destruction of red blood cells that cause the symptoms of PNH and other diseases mediated by abnormal complement pathway activity.
    • Lipodystrophy: Lipodystrophy is a rare metabolic disorder characterized by decreases in the quantity and distribution of body fat. This is often associated with low levels of a hormone called leptin. Low leptin leads to extreme hunger, disrupts the body’s metabolism and can cause fatty tissue to accumulate in muscles and organs such as the liver. Lipodystrophy can be inherited or acquired and affect people of all ages. We are testing a novel antibody that stimulates the leptin receptor to replace the deficient hormone.?We hope to learn whether this therapy improves the health of people living with different types of lipodystrophy.

    While?researching the genetics of rare disease and creating new therapeutics, we work closely with patient advocacy groups and the rare disease community?to listen, understand?and apply their experiences to our research. These insights?help us learn from those most intimately impacted by certain diseases, ensuring that we meet the needs of the community. This guidance helps to inform our clinical trial designs, clinical trial recruitment processes and therapeutic delivery systems. We celebrate and appreciate our relationships with the rare disease community and are proud to support the efforts of rare disease advocacy organizations.

  • CARDIOVASCULAR AND
    METABOLISM

  • Cardiovascular and metabolic disorders encompass a large number of diseases, including coronary artery disease and diabetes. Our current clinical programs focus on treating cardiovascular disease, the number one cause of morbidity and mortality in the United States and other developed countries, and on muscle-growth disorders.

  • INFECTIOUS DISEASES

  • We are advancing new approaches to address serious infections that impact vulnerable populations.

    In an increasingly interconnected world, infectious diseases are able to spread more quickly than in the past, enhancing their threat to global health and elevating the need for new treatments that are safe, effective and easily deployed.

    We?leverage?our proprietary?VelociSuite??‘rapid response’ technologies to create novel fully human monoclonal antibody?treatments, with the goal of addressing a number of common and newly emerging infectious diseases, such as COVID-19, Ebola and the Middle East respiratory syndrome (MERS) coronavirus.

  • INFLAMMATION AND
    IMMUNOLOGY

  • Inflammation is the body's natural protective response against injury and infections, including those caused by bacteria and viruses.

    But inflammation can also occur when the immune system triggers an inappropriate inflammatory response to the body's own cells, or responds excessively to external irritants such as pollen or certain foods. This inflammatory response is usually accompanied by the overproduction of certain proteins called cytokines, including interleukins, and can result in chronic and debilitating disease conditions such as rheumatoid arthritis, atopic dermatitis or asthma.

    One therapeutic approach is to block the actions of the cytokines that play a role in the development of these diseases.

  • ONCOLOGY

  • Despite decades of progress, cancer still remains one of the world's most serious health problems.

    Our approach to cancer is multi-faceted:

    • Immuno-Oncology works by unleashing the body's own immune system to eliminate or control cancer. We believe the most successful approaches will combine multiple innovative therapies acting on different pathways and targets, both in the patient's tumor as well as in their immune response, to precisely tailor the best treatments to the individual. We are currently exploring multiple approaches, including checkpoint inhibitors and bispecific antibodies
    • Anti-angiogenesis is the disruption of the blood flow to tumors by inhibiting the formation of new blood vessels. We continue to investigate the potential of novel approaches to inhibit angiogenesis, as well as the possibility of combination approaches that benefit from blocking angiogenesis and altering the tumor microenvironment
    • Antibody drug conjugates (ADCs) are novel combination therapies that enable the selective killing of cancer cells by joining cancer-targeting antibodies with a highly potent chemotherapy, or "warhead." ADCs are designed to take advantage of both the specificity of antibodies and the cancer-killing power of cytotoxic agents
    • Cancer cell dependencies are mutant or aberrant signaling pathways that are required by cancer cells for growth and survival, as a result of their specific oncogenic mutations. We are exploring novel antibody technologies to better target cancer cell dependencies
  • OPHTHALMOLOGY

  • We have a long-standing commitment to the treatment of serious, vision-threatening diseases.

    Our R&D programs target a number of mechanisms in retinal diseases in unique combinations with anti-Vascular Endothelial Growth Factor (VEGF) therapy, which employs Regeneron's proprietary "Trap" technology and is currently the standard-of-care for a number of retinal conditions. The VEGF protein is necessary to stimulate the formation of blood vessels that supply nutrients to tissues. However, excessive VEGF production can lead to retinal conditions in which blood vessels grow abnormally, become fragile, and vision is threatened due to fluid and blood leaking into surrounding tissue. If untreated, the swelling can damage cells, create blind spots in central vision and lead to permanent vision loss.

  • PAIN

  • We are advancing new non-opioid treatment options for patients suffering from a range of chronic pain conditions, including osteoarthritis pain and chronic back pain.

    Many of these patients are currently treated with opioid medicines, which can often come with unwanted side effects and the potential for abuse. We are leading the discovery and characterization of a new class of proteins, called neurotrophins, which promote the growth of nerve cells. Members of this family of proteins include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and others.

  • RARE DISEASES

  • At Regeneron, we believe in following sound and innovative science. We pursue foundational scientific research that can impact diseases with both large and small groups of patients. To do this research, we leverage cutting-edge research tools and resources such as the Regeneron Genetics Center to further understand the genetic variations that may protect someone from a disease or make them more susceptible. We then use Regeneron-invented technologies to further understand the root causes of disease and to identify potential new therapies. Through this approach, we have created numerous approved and investigational medicines for patients with rare and ultra-rare conditions.

    Our areas of rare disease research include:

    • Cryopyrin-Associated Periodic Syndromes (CAPS): CAPS is a group of illnesses characterized by lifelong, recurrent symptoms of rash, fever/chills, joint pain, eye redness/pain and fatigue. Our first FDA-approved drug, launched in 2008, treats aspects of this auto-inflammatory syndrome.
    • Fibrodysplasia Ossificans Progressiva (FOP): FOP is a progressive, severely disabling, life-altering disease in which muscles, ligaments, tendons and other connective tissues are transformed into bone. Scientists in our Skeletal Diseases Therapeutic Focus Area have been investigating FOP and related conditions for 20 years. Based on our novel discoveries about the functioning of this ultra-rare disease (with only 800 known patients in the world), we are studying a new, Regeneron-invented investigational treatment for people living with this condition.
    • Homozygous familial hypercholesterolemia (HoFH): People with HoFH have an inherited form of extremely high cholesterol and are unable to process the body's natural supply of cholesterol in the liver. Very high levels of LDL cholesterol can block arteries (atherosclerosis) and lead to a heart attack or stroke at a very young age. We are conducting various studies in HoFH, including an investigational, fully-human monoclonal antibody that specifically binds to and blocks a key protein in regulating LDL cholesterol levels.
    • Paroxysmal nocturnal hemoglobinuria (PNH): PNH is an ultra-rare, chronic, life-threatening disease in which genetic variants lead to increased risk for destruction of red blood cells, resulting in a range of symptoms including fatigue, shortness of breath and blood clots. We are exploring an investigational, fully-human monoclonal antibody designed to block and prevent the destruction of red blood cells that cause the symptoms of PNH and other diseases mediated by abnormal complement pathway activity.
    • Lipodystrophy: Lipodystrophy is a rare metabolic disorder characterized by decreases in the quantity and distribution of body fat. This is often associated with low levels of a hormone called leptin. Low leptin leads to extreme hunger, disrupts the body’s metabolism and can cause fatty tissue to accumulate in muscles and organs such as the liver. Lipodystrophy can be inherited or acquired and affect people of all ages. We are testing a novel antibody that stimulates the leptin receptor to replace the deficient hormone.?We hope to learn whether this therapy improves the health of people living with different types of lipodystrophy.

    While?researching the genetics of rare disease and creating new therapeutics, we work closely with patient advocacy groups and the rare disease community?to listen, understand?and apply their experiences to our research. These insights?help us learn from those most intimately impacted by certain diseases, ensuring that we meet the needs of the community. This guidance helps to inform our clinical trial designs, clinical trial recruitment processes and therapeutic delivery systems. We celebrate and appreciate our relationships with the rare disease community and are proud to support the efforts of rare disease advocacy organizations.

UNITED IN DISCOVERY

Along with our distinguished collaborators, we are uncovering cutting-edge scientific advances. Learn about our clinical-stage research partnerships and see how, together, we are changing the landscape of medicine.

Our collaborations

The People Behind the Science: Regeneron Scientist, Aynur

In 1980, a young Aynur Hermann sat transfixed in front of the television at her home in Germany as Carl Sagan explored the bounds of the universe in the popular Cosmos: A Personal Voyage television series. "I was completely hypnotized," she said. "I knew then that I could only work in science, and nothing else."

Read Aynur's story

黄色网站在线观看